异常剪接组织因子与肿瘤的关系

doi:10.3760/cma.j.issn.1673422X.2015.05.011

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (5): 361-363.doi: 10.3760/cma.j.issn.1673422X.2015.05.011

异常剪接组织因子与肿瘤的关系

苏州大学附属第一医院血液科江苏省血液研究所卫生部血栓与止血重点实验室血液学协同创新中心

出版日期:2015-05-08 发布日期:2015-05-12
通讯作者: 张日 zhang_r_i@163.com

Relation between alternatively spliced tissue factor and tumor

Department of Hematology, First Affiliated Hospital of Soochow University, Hematology Institute of Jiangsu, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Collaborative Innovation Center of Hematology

Online:2015-05-08 Published:2015-05-12
Contact: Zhang Ri zhang_r_i@163.com

摘要/Abstract

摘要： 丝氨酸/精氨酸富集蛋白（SR）、SR蛋白激酶等参与了异常剪接组织因子（asTF）的形成，近年发现asTF在肿瘤新生血管形成和肿瘤进展、转移等病理过程中发挥着一定的作用，在临床上对其检测将具有很大的意义。

赵林艳, 江波, 张日. 异常剪接组织因子与肿瘤的关系[J]. 国际肿瘤学杂志, 2015, 42(5): 361-363.

ZHAO Lin-Yan, JIANG Bo, ZHANG Ri. Relation between alternatively spliced tissue factor and tumor[J]. Journal of International Oncology, 2015, 42(5): 361-363.

［1］刘育成，陈群. 组织因子及其在凝血、非凝血功能中的研究进展［J］. 医学信息, 2011, 24(4): 24832485. ［2］ Mackman N, Morrissey JH, Fowler B, et al. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade［J］. Biochemistry, 1989, 28(4):17551762. ［3］ Kocaturk B, Versteeg HH. Tissue factor isoforms in cancer and coagulation: May the best isoform win［J］. Thromb Res, 2012, 129Suppl: S6975. ［4］ Chandradas S, Deikus G, Tardos JG, et al. Antagonistic roles of four SR proteins in the biosynthesis of alternatively spliced tissue factor transcripts in monocytic cells［J］. J Leukoc Biol, 2010, 87(1):147152. ［5］ Meseguer S, Mudduluru G, Escamilla JM, et al. MicroRNAs10a and 210b contribute to retinoic acidinduced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 (SF2/ASF)［J］. J Biol Chem, 2011, 286(6):41504164. ［6］ Wang N, Zhu M, Tsao SW, et al. MiR23amediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma［J］. Mol Cancer, 2013, 12(1):119. ［7］ Zhang X, Yu H, Lou JR, et al. MicroRNA19(miR19)regulate tissue factor expression in breast cancer cells［J］. J Biol Chem, 2011, 286(2):14291435. ［8］ Chuang TD, Luo X, Panda H, et al. miR93/106b and their host gene, MCM7, are differentially expressed in leiomyomas and functionally target F3 and IL8［J］. Mol Endocrinol, 2012, 26(6):10281042. ［9］ Leppert U, Eisenreich A. The role of tissue factor isoforms in cancer biology［J］. Int J Cancer, 2015, 137(3):497503. ［10］ Eisenreich A, Boltzen U, Malz R, et al. Overexpression of alternatively spliced tissue factor induces the proangiogenic properties of murine cardiomyocytic HL1 cells［J］. Circ J, 2011, 75(5):12351242. ［11］ van den Berg YW, Osanto S, Reitsma PH, et al. The relationship between tissue factor and cancer progression: insights from bench and bedside［J］. Blood, 2012, 119 (4):924932. ［12］ Mackman N, Davis GE. Blood coagulation and blood vessel development: is tissue factor the missing link? ［J］. Arterioscler Thromb Vasc Biol, 2011, 31(11):23642366. ［13］ nlü B, Versteeg HH. Effects of tumorexpressed coagulation factors on cancer progression and venous thrombosis: is there a key factor? ［J］. Thromb Res, 2014, 133Suppl 2:S7684. ［14］ Eisenreich A, Rauch U. Regulation and differential role of the tissue factor isoforms in cardiovascular biology［J］. Trends Cardiovasc Med, 2010, 20(6): 199203. ［15］ Eisenreich A, Zakrzewicz A, Huber K, et al. Regulation of proangiogenic tissue factor expression in hypoxiainduced human lung cancer cells［J］. Oncol Rep, 2013, 30(1):462470. ［16］ Debdab M, Carreaux F, Renault S, et al. Leucettines, a class of potent inhibitors of cdc2like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative preRNA splicing［J］. J Med Chem, 2011, 54(12):41724186. ［17］ Giannarelli C, Alique M, Rodriguez DT, et al. Alternatively spliced tissue factor promotes plaque angiogenesis through the activation of HIF1a and VEGF signaling［J］. Circulation, 2014, 130(15):12741286. ［18］ Rollin J, Regina S, Gruel Y. Tumor expression of alternatively spliced tissue factor is a prognostic marker in nonsmall cell lung cancer［J］. J Thromb Haemost, 2010, 8(3):607610. ［19］ Srinivasan R, Ozhegov E, van den Berg YW, et al. Splice variants of tissue factor promote monocyteendothelial interactions by triggering the expression of cell adhesion molecules via integrinmediated signaling［J］. J Thromb Haemost, 2011, 9(10):20872096. ［20］ Srinivasan R, Bogdanov VY. Splice variants of Tissue Factor and integrinmediated signaling［J］. Thromb Res, 2012, 129Suppl 2:S3437. ［21］ Kocatürk B, Van den Berg YW, Tieken C, et al. Alternatively spliced tissue factor promotes breast cancer growth in a β1 integrindependent manner［J］. Proc Natl Acad Sci USA, 2013, 110(28):1151711522. ［22］ Unruh D, Turner K, Srinivasan R, et al. Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma［J］. Int J Cancer, 2014, 134(1):920. ［23］ Rollin J, Regina S, Gruel Y. Tumor expression of alternatively spliced tissue factor is a prognostic marker in nonsmall cell lung cancer［J］. J Thromb Haemost, 2010, 8(3):607610.

异常剪接组织因子与肿瘤的关系

Relation between alternatively spliced tissue factor and tumor

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价